GSK vs Sanofi
GSK (GSK), health care, and Sanofi (SNY), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Sanofi is worth $115.1B on the stock market and GSK $99.3B: Sanofi is valued at 16% more. GSK trades at 17.3 times earnings and Sanofi at 23.9; operating margins in their latest fiscal years were 24.3% and 14.5%. Over the past year GSK's share price has moved +6.42% and Sanofi's -4.48%.
Key facts
- GSK market value
- $99.3B
- Sanofi market value
- $115.1B
- GSK P/E
- 17.3
- Sanofi P/E
- 23.9
- GSK revenue
- $43.4BFY to 2025-12-31
- Sanofi revenue
- $48.4BFY to 2025-12-31
- Superinvestors holding both
- 4
Market values as of .
| Measure | GSK | Sanofi |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $99.3Blower | $115.1Bhigher |
| Revenue | $43.4Blower | $48.4Bhigher |
| Earnings | $7.6Blower | $8.7Bhigher |
| Employees | 66,841lower | 74,846higher |
| Total assets | $81.1Blower | $140.7Bhigher |
| Valuation | ||
| P/E | 17.3lower | 23.9higher |
| P/S | 2.3lower | 2.4higher |
| P/B | — | — |
| Dividend yield | — | — |
| Profitability | ||
| Operating margin | 24.3%higher | 14.5%lower |
| Balance sheet | ||
| Net assets | $21.7Blower | $79.2Bhigher |
| Total liabilities | $59.9Blower | $61.1Bhigher |
| Total debt | $19.2Blower | $20.8Bhigher |
| Cash on hand | $4.5Blower | $8.5Bhigher |
| Price change | ||
| Today | -1.77%lower | -0.92%higher |
| 1 year | +6.42%higher | -4.48%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (4)
- Dodge & Cox team1.1% / 0.3%
- Charles Brandes (founder)0.5% / 1.2%
- Ken Fisher0.5% / 0.1%
- Richard Pzena<0.1% / <0.1%
GSK only (7)
- Thomas Kahn0.9%
- Primecap team0.8%
- Jeremy Grantham (co-founder)0.4%
- Tweedy, Browne team0.3%
- Steve Cohen0.2%
- Howard Gleicher0.1%
- Murray Stahl<0.1%
Sanofi only (3)
- Louis Bacon0.5%
- Sarah Ketterer0.4%
- Lee Ainslie<0.1%
Percentages are each holding's share of that investor's reported portfolio (under "Both": GSK / Sanofi). Who owns GSK · Who owns SNY
More on GSK
Further comparisons
GSK against its closest peers
Sanofi against its closest peers
Learn
Questions and answers
Which is bigger, GSK or Sanofi?
By market value, Sanofi is the larger: $115.1B against $99.3B for GSK. By revenue in its latest fiscal year, Sanofi is the larger: $48.4B against $43.4B for GSK.
Which has the higher P/E ratio?
Sanofi: 23.9, against 17.3 for GSK. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has the higher operating margin?
GSK: 24.3%, against 14.5% for Sanofi. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has more debt?
Sanofi: $20.8B, against $19.2B for GSK. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both GSK and Sanofi?
In their latest 13F filings, Dodge & Cox team, Charles Brandes (founder), Ken Fisher and Richard Pzena hold both.
Cite this page
Funkfolio, “GSK vs Sanofi”, data as of 17 November 2026. https://funkfolio.com/compare/gsk-vs-sny
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.